Literature DB >> 27579651

Genomic Classification in Acute Myeloid Leukemia.

Elli Papaemmanuil, Hartmut Döhner, Peter J Campbell.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27579651     DOI： 10.1056/NEJMc1608739

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  50 in total

1.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

2.  Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Authors:  Luise Hartmann; Claudia Haferlach; Manja Meggendorfer; Niroshan Nadarajah; Wolfgang Kern; Torsten Haferlach; Anna Stengel
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

3.  Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

Authors:  Blake S Moses; Samantha McCullough; Jennifer M Fox; Bryan T Mott; Søren M Bentzen; MinJung Kim; Jeffrey W Tyner; Rena G Lapidus; Ashkan Emadi; Michelle A Rudek; Tami J Kingsbury; Curt I Civin
Journal:  Blood Adv       Date:  2021-02-09

Review 4.  The evidence framework for precision cancer medicine.

Authors:  Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2017-12-19       Impact factor: 66.675

5.  The growing landscape of FLT3 inhibition in AML.

Authors:  Catherine C Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  "Epigenetic" modification as therapy for acute myeloid leukemia.

Authors:  Charles A Schiffer
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

Review 7.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

8.  Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Authors:  Theodore C Tarver; Jason E Hill; Leena Rahmat; Alexander E Perl; Erkut Bahceci; Kenichi Mori; Catherine C Smith
Journal:  Blood Adv       Date:  2020-02-11

9.  A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

Authors:  Catherine C Smith; Mark J Levis; Olga Frankfurt; John M Pagel; Gail J Roboz; Richard M Stone; Eunice S Wang; Paul L Severson; Brian L West; Mai H Le; Sabine Kayser; Bao Lam; Henry H Hsu; Chao Zhang; Gideon Bollag; Alexander E Perl
Journal:  Blood Adv       Date:  2020-04-28

10.  Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Authors:  Nikola P Konstandin; Friederike Pastore; Tobias Herold; Annika Dufour; Maja Rothenberg-Thurley; Tanja Hinrichsen; Bianka Ksienzyk; Sebastian Tschuri; Stephanie Schneider; Eva Hoster; Wolfgang E Berdel; Bernhard J Woermann; Maria C Sauerland; Jan Braess; Stefan K Bohlander; Hanns-Georg Klein; Wolfgang Hiddemann; Klaus H Metzeler; Karsten Spiekermann
Journal:  Blood Adv       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.